{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:49:56Z","timestamp":1790736596107,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40265-019-01129-6","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T05:50:00Z","timestamp":1557985800000},"page":"863-874","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy"],"prefix":"10.1007","volume":"79","author":[{"given":"Yvette N.","family":"Lamb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma D.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,16]]},"reference":[{"key":"1129_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.","journal-title":"Orphanet J Rare Dis."},{"issue":"7","key":"1129_CR2","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1111\/j.1742-4658.2007.05712.x","volume":"274","author":"X Hou","year":"2007","unstructured":"Hou X, Aguilar M-I, Small DH. Transthyretin and familial amyloidotic polyneuropathy: recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J. 2007;274(7):1637\u201350.","journal-title":"FEBS J."},{"issue":"1","key":"1129_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13023-017-0726-x","volume":"13","author":"Y Sekijima","year":"2018","unstructured":"Sekijima Y, Ueda M, Koike H, et al. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis. 2018;13(1):6.","journal-title":"Orphanet J Rare Dis."},{"issue":"5","key":"1129_CR4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/mus.26034","volume":"57","author":"HH Schmidt","year":"2018","unstructured":"Schmidt HH, Waddington-Cruz M, Botteman MF, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018;57(5):829\u201337.","journal-title":"Muscle Nerve."},{"issue":"Suppl 1","key":"1129_CR5","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","volume":"29","author":"D Adams","year":"2016","unstructured":"Adams D, Suhr OB, Hund E, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016;29(Suppl 1):S14\u201326.","journal-title":"Curr Opin Neurol."},{"issue":"8","key":"1129_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","volume":"47","author":"PN Hawkins","year":"2015","unstructured":"Hawkins PN, Ando Y, Dispenzeri A, et al. Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015;47(8):625\u201338.","journal-title":"Ann Med."},{"issue":"9","key":"1129_CR7","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","volume":"99","author":"BG Ericzon","year":"2015","unstructured":"Ericzon BG, Wilczek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20\u00a0years still the best therapeutic alternative? Transplantation. 2015;99(9):1847\u201354.","journal-title":"Transplantation."},{"issue":"3","key":"1129_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/jcpt.12145","volume":"39","author":"Y Sekijima","year":"2014","unstructured":"Sekijima Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. J Clin Pharm Ther. 2014;39(3):225\u201333.","journal-title":"J Clin Pharm Ther."},{"key":"1129_CR9","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s00415-017-8708-4","volume":"265","author":"V Plante-Bordenave","year":"2018","unstructured":"Plante-Bordenave V. Transthyretin familial amyloid polyneuropathy: an update. J Neurol. 2018;265:976\u201383.","journal-title":"J Neurol."},{"issue":"1","key":"1129_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","volume":"5","author":"T Coelho","year":"2016","unstructured":"Coelho T, Merlini G, Bulawa CE, et al. Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurol Ther. 2016;5(1):1\u201325.","journal-title":"Neurol Ther."},{"issue":"12","key":"1129_CR11","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s40265-014-0260-2","volume":"74","author":"LJ Scott","year":"2014","unstructured":"Scott LJ. Tafamidis: a review of its use in familial amyloid polyneuropathy. Drugs. 2014;74(12):1371\u20138.","journal-title":"Drugs."},{"issue":"24","key":"1129_CR12","doi-asserted-by":"publisher","first-page":"9629","DOI":"10.1073\/pnas.1121005109","volume":"109","author":"CE Bulawa","year":"2012","unstructured":"Bulawa CE, Connelly S, DeVit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA. 2012;109(24):9629\u201334.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1129_CR13","unstructured":"European Medicines Agency. Vyndaqel (tafamidis) 20\u00a0mg soft capsules: summary of product characteristics. 2016. \n                    http:\/\/www.ema.europa.eu\/\n                    \n                  . Accessed 2 May 2019."},{"issue":"8","key":"1129_CR14","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785\u201392.","journal-title":"Neurology."},{"issue":"11","key":"1129_CR15","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","volume":"260","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maia LF, Martins da Silva A, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260(11):2802\u201314.","journal-title":"J Neurol."},{"issue":"3","key":"1129_CR16","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","volume":"24","author":"FA Barroso","year":"2017","unstructured":"Barroso FA, Judge DP, Ebede B, et al. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid. 2017;24(3):194\u2013204.","journal-title":"Amyloid."},{"key":"1129_CR17","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jns.2016.01.046","volume":"362","author":"Y Ando","year":"2016","unstructured":"Ando Y, Sekijima Y, Obayashi K, et al. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: a phase III, open-label study. J Neurol Sci. 2016;362:266\u201371.","journal-title":"J Neurol Sci."},{"issue":"6","key":"1129_CR18","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","volume":"6","author":"G Merlini","year":"2013","unstructured":"Merlini G, Plant\u00e9-Bordeneuve V, Judge DP, et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013;6(6):1011\u201320.","journal-title":"J Cardiovasc Transl Res."},{"key":"1129_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s13023-018-0947-7","volume":"13","author":"L Amass","year":"2018","unstructured":"Amass L, Li H, Gundapaneni B, et al. Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy. Orphanet J Rare Dis. 2018;13:225.","journal-title":"Orphanet J Rare Dis."},{"issue":"3","key":"1129_CR20","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/ene.13510","volume":"25","author":"BK Gundapaneni","year":"2018","unstructured":"Gundapaneni BK, Sultan MB, Keohane DJ, et al. Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2018;25(3):464\u20138.","journal-title":"Eur J Neurol."},{"issue":"1","key":"1129_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/13506129.2017.1301419","volume":"24","author":"D Keohane","year":"2017","unstructured":"Keohane D, Schwartz J, Gundapaneni B, et al. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid. 2017;24(1):30\u20136.","journal-title":"Amyloid."},{"issue":"3","key":"1129_CR22","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/13506129.2016.1207163","volume":"23","author":"M Waddington Cruz","year":"2016","unstructured":"Waddington Cruz M, Amass L, Keohane D, et al. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid. 2016;23(3):178\u201383.","journal-title":"Amyloid."},{"issue":"21","key":"1129_CR23","doi-asserted-by":"publisher","first-page":"e1999","DOI":"10.1212\/WNL.0000000000006543","volume":"91","author":"T Coelho","year":"2018","unstructured":"Coelho T, In\u00eas M, Concei\u00e7\u00e3o I, et al. Natural history and survival in stage I Val30Met transthyretin familial amyloid polyneuropathy. Neurology. 2018;91(21):e1999\u20132009.","journal-title":"Neurology."},{"issue":"5","key":"1129_CR24","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1007\/s00415-016-8064-9","volume":"263","author":"A Cortese","year":"2016","unstructured":"Cortese A, Vita G, Luigetti M, et al. Monitoring effectiveness and safety of tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. J Neurol. 2016;263(5):916\u201324.","journal-title":"J Neurol."},{"issue":"1","key":"1129_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40120-018-0097-9","volume":"7","author":"R Mundayat","year":"2018","unstructured":"Mundayat R, Stewart M, Alvir J, et al. Positive effectiveness of tafamidis in delaying disease progression in transthyretin familial amyloid polyneuropathy up to 2\u00a0years: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Neurol Ther. 2018;7(1):87\u2013101.","journal-title":"Neurol Ther."},{"issue":"2","key":"1129_CR26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00415-016-8337-3","volume":"264","author":"V Plante-Bordeneuve","year":"2017","unstructured":"Plante-Bordeneuve V, Gorram F, Salhi H, et al. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study. J Neurol. 2017;264(2):268\u201376.","journal-title":"J Neurol."},{"issue":"Suppl 1","key":"1129_CR27","first-page":"S77","volume":"3","author":"S Sousa","year":"2016","unstructured":"Sousa S, Valdrez K, Fonseca I, et al. Prediction of nerve conduction studies outcomes in patients with familial amyloidotic polyneuropathy receiving tafamidis therapy. J Neuromuscul Dis. 2016;3(Suppl 1):S77\u20138.","journal-title":"J Neuromuscul Dis."},{"key":"1129_CR28","unstructured":"European Medicines Agency. Tafamidis: CHMP assessment report. 2011. \n                    http:\/\/www.ema.europa.eu\/\n                    \n                  . Accessed 2 May 2019."},{"issue":"2","key":"1129_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s12265-015-9613-9","volume":"8","author":"T Damy","year":"2015","unstructured":"Damy T, Judge DP, Kristen AV, et al. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. J Cardiovasc Transl Res. 2015;8(2):117\u201327.","journal-title":"J Cardiovasc Transl Res."},{"key":"1129_CR30","unstructured":"Pfizer Inc. Vyndaqel\u00ae capsules 20\u00a0mg: Japanese prescribing information. 2016. \n                    http:\/\/www.pmda.go.jp\/\n                    \n                  . Accessed 2 May 2019."},{"issue":"2","key":"1129_CR31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40267-016-0368-4","volume":"33","author":"K McKeage","year":"2017","unstructured":"McKeage K, Lyseng-Williamson KA, Scott LJ. Tafamidis in transthyretin amyloidosis: a guide to its use in delaying peripheral neurological impairment in patients with stage 1 polyneuropathy. Drug Ther Perspect. 2017;33(2):47\u201353.","journal-title":"Drug Ther Perspect."},{"issue":"9","key":"1129_CR32","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1590\/0004-282x20180094","volume":"76","author":"MV Pinto","year":"2018","unstructured":"Pinto MV, Barreira AA, Bulle AS, et al. Brazilian consensus for diagnosis, management and treatment of transthyretin familial amyloid polyneuropathy. Arq Neuropsiquiatr. 2018;76(9):609\u201321.","journal-title":"Arq Neuropsiquiatr."},{"key":"1129_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40265-017-0842-x","volume":"78","author":"SJ Keam","year":"2018","unstructured":"Keam SJ. Inotersen: first global approval. Drugs. 2018;78:1\u20136.","journal-title":"Drugs."},{"key":"1129_CR34","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","volume":"78","author":"S Hoy","year":"2018","unstructured":"Hoy S. Patisiran: first global approval. Drugs. 2018;78:1625\u201331.","journal-title":"Drugs."},{"key":"1129_CR35","unstructured":"Alnylam Pharmaceuticals Inc. ONPATTRO (patisiran) lipid complex injection, for intravenous use. 2018. \n                    http:\/\/www.alnylam.com\/\n                    \n                  . Accessed 2 May 2019."},{"key":"1129_CR36","unstructured":"Ionis Pharmaceuticals Inc. TEGSEDI (inotersen) injection, for subcutaneous use. 2018. \n                    http:\/\/tegsedi.com\/\n                    \n                  . Accessed 2 May 2019."},{"issue":"3","key":"1129_CR37","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11910-013-0435-3","volume":"14","author":"D Adams","year":"2014","unstructured":"Adams D, Th\u00e9audin M, Cauquil C, et al. FAP neuropathy and emerging treatments. Curr Neurol Neurosci Rep. 2014;14(3):435.","journal-title":"Curr Neurol Neurosci Rep."},{"issue":"6","key":"1129_CR38","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/ana.24519","volume":"78","author":"L-L Mariani","year":"2015","unstructured":"Mariani L-L, Lozeron P, Th\u00e9audin M, et al. Genotype-phenotype correlation and course of transthyretin familial amyoid polyneuropathies in France. Ann Neurol. 2015;78(6):901\u201316.","journal-title":"Ann Neurol."},{"issue":"12","key":"1129_CR39","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1111\/ene.12225","volume":"20","author":"P Lozeron","year":"2013","unstructured":"Lozeron P, Theaudin M, Mincheva Z, et al. Effect on disability and safety of tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2013;20(12):1539\u201345.","journal-title":"Eur J Neurol."},{"key":"1129_CR40","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"27","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;27:1007\u201316.","journal-title":"N Engl J Med."},{"issue":"4","key":"1129_CR41","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s10072-019-03778-7","volume":"40","author":"G Vita","year":"2019","unstructured":"Vita G, Vita GL, Stancanelli C, et al. Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies. Neurol Sci. 2019;40(4):661\u20139.","journal-title":"Neurol Sci."},{"issue":"4","key":"1129_CR42","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/14656566.2018.1554648","volume":"20","author":"V Plante-Bordeneuve","year":"2018","unstructured":"Plante-Bordeneuve V, Lin H, Gollob J, et al. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy. Expert Opin Pharmacother. 2018;20(4):473\u201381.","journal-title":"Expert Opin Pharmacother."},{"issue":"6","key":"1129_CR43","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/bcp.12561","volume":"79","author":"KJ Klamerus","year":"2015","unstructured":"Klamerus KJ, Watsky E, Moller R, et al. The effect of tafamidis on the QTc interval in healthy subjects. Br J Clin Pharmacol. 2015;79(6):918\u201325.","journal-title":"Br J Clin Pharmacol."},{"issue":"2","key":"1129_CR44","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40120-014-0023-8","volume":"3","author":"OB Suhr","year":"2014","unstructured":"Suhr OB, Conceicao IM, Karayal ON, et al. Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurol Ther. 2014;3(2):101\u201312.","journal-title":"Neurol Ther."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01129-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01129-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01129-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T11:54:10Z","timestamp":1589889250000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01129-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,16]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["1129"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01129-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,16]]},"assertion":[{"value":"16 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yvette Lamb and Emma Deeks are salaried employees of Adis\/Springer, responsible for the article content and declare no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}